Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Net revenue:
Total net revenue		$ 116,275	$ 97,459	$ 223,717	$ 182,791
Cost of revenue:
Total cost of revenue	[1]	73,648	56,628	141,566	106,557
Gross profit		42,627	40,831	82,151	76,234
Operating expenses:
Research and development	[2]	14,697	11,956	29,079	24,104
Selling and marketing		13,233	10,348	24,504	19,246
General and administrative		10,716	10,328	22,176	19,217
Total operating expenses		38,646	32,632	75,759	62,567
Income from operations		3,981	8,199	6,392	13,667
Income (loss) on equity method investment, net		(832)	1,117	(1,172)	1,089
Other expense, net		(2,490)	(4,260)	(5,158)	(8,954)
Income before provision for income taxes		659	5,056	62	5,802
Provision for income taxes		480	287	911	631
Net income (loss)		$ 179	$ 4,769	$ (849)	$ 5,171
Net income (loss) per share - basic		$ 0.00	$ 0.05	$ (0.01)	$ 0.06
Net income (loss) per share - diluted		$ 0.00	$ 0.05	$ (0.01)	$ 0.06
Weighted average common shares used in computing net income per share:
Basic		91,761	92,025	91,299	91,609
Diluted		93,932	93,353	91,299	92,607
Net income (loss)		$ 179	$ 4,769	$ (849)	$ 5,171
Foreign currency translation adjustment		(108)	1,809	123	3,302
Comprehensive income (loss)		71	6,578	(726)	8,473
Products
Net revenue:
Total net revenue	[3]	60,721	41,805	113,480	73,063
Cost of revenue:
Total cost of revenue		35,520	23,102	67,029	41,528
Services
Net revenue:
Total net revenue	[4]	55,554	55,654	110,237	109,728
Cost of revenue:
Total cost of revenue		$ 38,128	$ 33,526	$ 74,537	$ 65,029

[1] Includes cost of revenue from sales to the China joint venture, an equity method investment of $6,203 and $14,248 for the three and six months ended December 31, 2021 and $2,757 and $4,701 for the three and six months ended December 31, 2020, respectively.

[2] Includes chargeback to the China joint venture, an equity method investment related to research and development project of $415 and $994 for the three and six months ended December 31, 2021 and $430 for the three and six months ended December 31, 2020.

[3] Includes sales to the China joint venture, an equity method investment of $8,816 and $14,735 for the three and six months ended December 31, 2021 and $1,446 and $4,320 for the three and six months ended December 31, 2020, respectively. See Note 14.

[4] Includes sales to the China joint venture, an equity method investment of $2,679 and $5,494 for the three and six months ended December 31, 2021 and $3,186 and $5,262 for the three and six months ended December 31, 2020, respectively. See Note 14.